Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...
This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing. Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm ...
Paul M. Friedman, MD - Dermatologist in Houston and New York Click here for high-resolution version HOUSTON, TX--(Marketwired - Jun 5, 2014) - Dr. Paul M. Friedman, a board-certified dermatologist in ...
Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...
NEWPORT BEACH, CA--(Marketwired - Sep 22, 2015) - Dr. Nancy Silverberg, a dermatologist in Newport Beach, believes that looking younger can help patients feel younger, which can improve their overall ...
IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...
The latest facial filler on the market is taking the cosmetic world by storm.It’s called Juvederm Voluma XC, but it’s how long this filler lasts that has people flocking to doctors’ offices looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback